Evaluation of the Efficacy of Neoadjuvant Combined Therapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma
Head and Neck Diseases Conflux · 2025
DOI: 10.71321/dwr8tx96 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head and Neck Diseases Conflux, 2025. Verfasst von Nuo Chen und 2 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Our study aimed to assess the effectiveness and safety of neoadjuvant therapy involving the immune checkpoint inhibitor Nimotuzumab and programmed cell death ligand 1 (PD-L1) inhibitors, along with platinum and paclitaxel chemotherapy in individuals diagnosed with the head and neck squamous cell carcinoma (HNSCC).
Method
Over the course of 2024 and 2025, a cohort of 33 patients with locally advanced HNSCC admitted to our institution was included in the investigation. Stratification into three groups was based on the expression levels of epidermal growth factor receptor (EGFR) and PD-L1 in tumour tissues. The patients were treated with Nimotuzumab and PD-L1 inhibitors along with platinum and paclitaxel chemotherapy for three cycles. After three cycles of neoadjuvant therapy, some patients were given surgical treatment. The primary metrics for evaluating treatment success were the objective response rate (ORR) and the disease control rate (DCR). Secondary endpoints included pathological complete response rate, laryngeal preservation rate, and incidence of chemotherapy-related toxicities.
Results
The study results revealed promising tumour response among the 33 patients, with an objective response rate of 75.8%. One patient achieved a complete radiographic response. Twenty patients achieved radiologic response, with T-stage downstaging observed in 60.6% and N-stage downstaging in 27.3% of these cases. Seven patients underwent surgery following neoadjuvant therapy, with five of these patients successfully undergoing larynx-preserving hypopharyngeal cancer radical resections. Regarding adverse events, 21.2% of patients experienced leukopenia; 42.4% experienced anemia; 3.0%, hepatic impairment; and 9.1%, gastrointestinal reactions.
Conclusion
Neoadjuvant combination therapy significantly enhances tumour response rates in HNSCC, with most patients with laryngeal cancer retaining laryngeal function. Adverse reactions remain clinically manageable, and the majority of patients tolerate the treatment well.
Zitieren
APA
Chen, N., Wang, D., & Gao, C. (2025). Evaluation of the Efficacy of Neoadjuvant Combined Therapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma. Head and Neck Diseases Conflux. https://doi.org/10.71321/dwr8tx96
Vancouver
Chen N, Wang D, Gao C. Evaluation of the Efficacy of Neoadjuvant Combined Therapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma. Head and Neck Diseases Conflux. 2025. doi:10.71321/dwr8tx96
BibTeX
@article{Chen2025,
author = {Chen, Nuo and Wang, Dong and Gao, Chaobing},
title = {Evaluation of the Efficacy of Neoadjuvant Combined Therapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma},
journal = {Head and Neck Diseases Conflux},
year = {2025},
doi = {10.71321/dwr8tx96}
}
EUVIMED